



March 2023

Attention Prescriber: Discontinue Drugs Coverage

The New York State EPIC Program will discontinue coverage of drugs manufactured by GlaxoSmithKline LLC (GSK) for claims submitted with a date-of-service that is on or after July 1, 2023, because the manufacturer has withdrawn from EPIC Manufacturers Rebate Program. New York State legislation requires manufacturer participation in the rebate program for EPIC to cover its products.

The following chart lists the GSK drugs being used that EPIC will no longer be able to cover as of July 1, 2023.

Advair Diskus	Beconase AQ	Flovent Diskus	Lamictal	Valtrex
Advair HFA	Breo Ellipta	Flovent HFA	Lamictal XR	Ventolin HFA
Anoro Ellipta	Coreg	Imitrex	Nucala	Wellbutrin SR
Arnuity Ellipta	Coreg CR	Incruse Ellipta	Serevent Diskus	
Avodart	Epivir HBV	Jalyn	Trelegy Ellipta	

EPIC members using GSK products have been notified these drugs will no longer be covered by EPIC as of July 1, 2023. They have been advised to contact their prescriber for alternative drugs or they can pay the full out-of-pocket Medicare Part D cost of GSK products if they choose to continue using them.

We appreciate your cooperation in this matter and your continued support of the EPIC program. If you have any questions, please call the EPIC Provider Helpline at 1-800-634-1340.